Sara Nochur is an independent member of the board of City Therapeutics.  Dr. Nochur has 35 years of drug development and industry leadership experience with a focus on regulatory affairs. Most recently, she served as chief diversity, equity and inclusion officer at Alnylam Pharmaceuticals. Prior to that, Dr. Nochur was Alnylam’s chief regulatory officer. In that role, she built a large international regulatory affairs team. She led and pioneered the development and global approval of four novel RNAi therapeutics including ONPATTRO®, GIVLAARI®, OXLUMO® and LEQVIO®, paving the way for this new class of medicines to become a reality for rare as well as prevalent diseases. While at Alnylam, she was a member of the management board for several years and served as interim head of both quality assurance and medical affairs.

Prior to her 18 years at Alnylam, Dr. Nochur held leadership roles in regulatory affairs at The Medicines Company, Ceremedix and BioTrack, and in new product development and diagnostics with DynaGen. She is a prior board director of Marinus Pharmaceuticals and Decibel Therapeutics. Currently, Dr. Nochur sits on the board of the Biomedical Science Careers Program, a non-profit that increases representation of underrepresented minority and disadvantaged individuals in science and medicine, and Hospitality Homes, which provides free or low-cost housing for patients and caregivers receiving specialty medical care in Boston-area hospitals.

Dr. Nochur holds a PhD in biochemical engineering from Massachusetts Institute of Technology and M.S. and B.S. degrees from the University of Bombay.